Abstracts tagged "Scleroderma"

Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Francesco Bonomi¹, Cosimo Bruni², Silvia Laura Bosello³, Fabio Cacciapaglia⁴, Corrado Campochiaro⁵, Roberto Caporali⁶, Veronica Codullo⁷, Maria Antonietta D'Agostino⁸, Lorenzo Dagna⁹, Rossella De Angelis¹⁰, Giacomo de Luca¹¹, Dilia Giuggioli¹², Serena Guiducci¹³, Florenzo Iannone¹⁴, Francesca Ingegnoli¹⁵, Carlomaurizio Montecucco⁷, Valeria Riccieri¹⁶, Clodoveo Ferri¹⁷, Marco Matucci-Cerinic¹⁸ and Silvia Bellando Randone¹⁹, ¹University Hospital Careggi, Florence, Florence, Toscana, Italy, ²University of Zurich, Zurich, Switzerland, ³Division of Rheumatology and Clinical Immunology - Catholic University of the Sacred Heart, Rome, Italy, Rome, Italy, ⁴Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁵IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ⁶University of Milan and ASST Gaetano Pini-CTO, Milano, Italy, ⁷Policlinico San Matteo, Pavia, Pavia, Italy, ⁸Catholic University of the Sacred Heart, Rome, Rome, Italy, ⁹Ospedale San Raffaele, Milano, Italy, ¹⁰Polytechnic University of Marche, Ancona, Ancona, Italy, ¹¹Vita-Salute San Raffaele University. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milan, Italy, ¹²Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., Modena, Emilia-Romagna, Italy, ¹³Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, Florence, Italy, ¹⁴Rheumatology DiMePReJ, University of Bari, School of Medicine, Bari, Italy, Bari, Italy, ¹⁵Clinica Reumatologica, Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza ²⁰²³-²⁰²⁷, Università degli Studi di Milano, Milan, Italy, Milan, Italy, ¹⁶Sapienza University of Rome, Rheumatology Clinic, Rome, Italy, Roma, Italy, ¹⁷University of Modena and Reggio Emilia, Modena, Modena, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹University of Florence, Florence, Italy
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…
Abstract Number: 1591 • ACR Convergence 2025
Novel autoantibodies in patients with systemic sclerosis and gastrointestinal dysfunction provide insight into disease pathogenesis
Zsuzsanna McMahan¹, Claudia Pedroza², Katie Lee³, Bingrui Chen³, Ami Shah⁴, Jody Hooper⁵, Srinivas Puttapaka⁶, Livia Casciola-Rosen⁷ and Subhash Kulkarni⁸, ¹UT Health Houston, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston, Houston, TX, ⁴Johns Hopkins Rheumatology, Baltimore, MD, ⁵Stanford University, Stanford, CA, ⁶BIDMC/Harvard, Boston, MA, ⁷Johns Hopkins University, Baltimore, MD, ⁸BIDMC, Boston, MA
Background/Purpose: Gastrointestinal (GI) dysfunction is common and often debilitating in systemic sclerosis (SSc). Though it affects most patients, mechanisms are poorly understood and biomarkers for…
Abstract Number: 0997 • ACR Convergence 2025
Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan 
Olivia Pryor¹, Catalina Burbano², Nathaniel Bagge², Rutuja Kulkarni², Heather F. Jones², Livio Dukaj², Shoshana M.K. Bloom², Jackson Lirette², Rachel Lent², Prachi Dhanania², Nicole A. Ladd², Ryan Kritzer², Hana Husic², Shobitha Jillella², Candace R. Perullo², Jinyu Zhu², Teagan J. Parsons², Ira Jain², Rakshika Balasubramaniyam², Kenneth L. Jahan², Vivin Karthik², Alexander Cristofaro¹, Chandan K. Pavuluri², Jenna LaBelle², Laurie Barefoot², Shrikanta Chattopadhyay², Kim M. Cirelli², Mollie M. Jurewicz², Andrew P. Ferretti² and Cagan Gurer², ¹TScan Therapeutics, Waltham, ²TScan Therapeutics, Waltham, MA
Background/Purpose: Selective modulation of autoimmune responses through antigen-specific therapies represents a promising direction for improving treatment specificity and safety. Genetic associations with HLA class II…
Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Benjamin Chaigne¹, Alexandre bense², Frédérique Aubourg³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Gregory Pugnet⁶, Eric Hachulla⁷, Vincent Cottin⁸, Arnaud Hot⁸, bertrand Dunogue¹, Anuxcy Kanagaratnam², Sylvain Palat⁹, Alain Lescoat¹⁰, Sabine berthier¹¹, Emmanuel Chatelus¹², Sébastien Rivière¹³, David Launay¹⁴, Marie-Elise Truchetet¹⁵, Anh-Tuan Dinh-Xuan³ and Luc Mouthon¹, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²AP HP, Paris, France, ³Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Montpelliers, France, ⁷CHU, Lilles, France, ⁸CHU, Lyon, France, ⁹Limoges, Limoges, France, ¹⁰CHU Rennes - University Rennes, Rennes, France, ¹¹CHU, Dijon, France, ¹²Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹³AP HP, Parsi, France, ¹⁴Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ¹⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…
Abstract Number: 2478 • ACR Convergence 2025
Endothelial Cell Biomarker Expression Suggests Increased Cell Adhesion in Juvenile SSc, Increased Cytokine Expression in JDM, and an Intermediate Phenotype in Overlap Syndrome Patients
Daniel Barnett¹, Alyssa Rosek², Yi-Chen Chen³, Alexander Cai⁴, Deren Esencan⁵, Sophia Matossian⁶, Christine Goudsmit⁷, Haley Havrilla⁸, Anwesha Sanyal⁹, Julie Sturza¹⁰, Pei-Suen Tsou⁶, Kathryn Torok⁹ and Jessica Turnier¹¹, ¹Division of Pediatric Rheumatology, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵¹. Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁶University of Michigan, Ann Arbor, MI, ⁷University of Michigan, Ann Arbor, ⁸Division of Pediatric Rheumatology, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰Division of Pediatric Rheumatology, CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, Ann Arbor, MI, ¹¹University of Michigan, Saline, MI
Background/Purpose: Vasculopathy is a central driving clinical, histopathologic and pathogenic feature of juvenile systemic scleroderma (jSSc), juvenile dermatomyositis (JDM) and juvenile scleroderma-overlap syndrome (jOverlap). While…
Abstract Number: 1590 • ACR Convergence 2025
Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
Yuzo Ikari¹, Poulami Dey², James St. Clair³, Anna Webber⁴, Caroline Foster⁵, Yi-Chen Chen⁵, Ramadan Ali⁶, Dinesh Khanna⁷, David Fox⁸ and Pei-Suen Tsou⁷, ¹Division of Rheumatology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan, ²Michigan Medicine, Ann Arbor, MI, ³University of Michigan, Ann Arbor, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan, ANN ARBOR, MI, ⁶University of Michigan, Ann Arobr, MI, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Michigan, Dexter, MI
Background/Purpose: Soluble CD13 (sCD13), released by the cleavage of cell surface CD13 by matrix metalloproteinase-14 (MMP14), has potent proinflammatory, angiogenic, and arthritogenic activities. The receptors…
Abstract Number: 0972 • ACR Convergence 2025
Prominent endothelial senescence in systemic sclerosis skin
Poulami Dey¹, William D Brodie², Megan N Mattichak³, Alexander Cai³, Qi Wu⁴, Johann Gudjonsson⁵, Dinesh Khanna⁵, John Varga⁵ and Pei-Suen Tsou⁵, ¹Michigan Medicine, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴Michigan Medicine, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…
Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 2471 • ACR Convergence 2025
Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
Borja del Carmelo Gracia Tello¹, Gema María Lledó Ibáñez², Luis Sáez Comet³ and Eduardo Ramos ibáñez⁴, ¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁴Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold capillaroscopy is a key tool in the early diagnosis of systemic sclerosis and related disorders. However, incorrect image acquisition can lead to misclassification…
Abstract Number: 1589 • ACR Convergence 2025
Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
Punchalee Kaenmuang¹, Nina Goldman², Arthihai Srirangan¹, Fiammetta Danzo¹, Wing-Ho Yip¹, Ali Taki³, Shereen Boreland¹, Benedetta Vitri¹, Carmel JW. Stock¹, Christopher Denton⁴, Athol U. Wells¹, Voon H. Ong⁵, Piersante Sestini⁶ and Elisabetta A. Renzoni¹, ¹Interstitial Lung Disease Unit, Royal Brompton Hospital, Guy’s and St Thomas’ National Health Service Foundation Trust, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ³Royal Free Hospital, London, England, United Kingdom, ⁴University College London, UK, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁶Department of Medical and Surgical Sciences and Neurosciences, University of Siena, Siena, Toscana, Italy
Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…
Abstract Number: 0971 • ACR Convergence 2025
Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
Neha Khanna¹, Alyssa Rosek¹, Alexander Cai¹, Olesya Plazyo², Johann Gudjonsson², Dinesh Khanna² and Pei-Suen Tsou², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by excessive collagen production, leading to the thickening and hardening of skin and internal organs.…
Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Alex Luta¹, Saloni Mitchell² and Virginia Steen³, ¹Hospital for Special Surgery, New York, NY, ²Mount Sinai West and Morningside, New York, NY, ³Georgetown University School of Medicine, Washington, DC
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…
Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Rachel Guess¹, Megan Curran², Lisa Zickuhr³ and Rachel Moquin¹, ¹Washington University School of Medicine, St. Louis, MO, ²University of Colorado | Children's Hospital Colorado, Aurora, CO, ³Washington University/B-JH/SLCH Consortium, St. Louis, MO
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…
Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Marissa Savoie¹, Monica Harding², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon¹, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin¹, Dorota Lebiedz-Odrobina², Yiming Luo⁴, Ashima Makol¹¹, Maureen Mayes¹², Zsuzsanna McMahan¹³, Jerry Molitor¹⁴, Duncan Moore¹⁵, Carrie Richardson¹⁶, Nora Sandorfi¹⁷, Ami Shah⁹, Ankoor Shah¹⁸, Brian Skaug¹⁹, Virginia Steen²⁰, Elizabeth Volkmann²¹, Carleigh Zahn¹⁰ and Flavia Castelino²², ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University, Stanford, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Mayo Clinic, Rochester, MN, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³UT Health Houston, Houston, TX, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Northwestern Memorial Hospital, Chicago, IL, ¹⁶Northwestern University, Chicago, IL, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Duke University, Durham, NC, ¹⁹UTHealth Houston Division of Rheumatology, Houston, TX, ²⁰Georgetown University School of Medicine, Washington, DC, ²¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²²Massachusetts General Hospital, Boston, MA
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
Abstract Number: 0965 • ACR Convergence 2025
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
Kamal Saba¹, Rong Huang², Priyanka Verma¹, M Asif Amin¹ and John Varga¹, ¹University of Michigan, Ann Arbor, MI, ²Purdue University, West Lafayette, IN
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…

1
2
3
…
33
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].